Checkpoint Inhibitor
Recently Published Documents


TOTAL DOCUMENTS

2848
(FIVE YEARS 2737)

H-INDEX

52
(FIVE YEARS 44)

2022 ◽  
Vol 162 ◽  
pp. 22-33
Author(s):  
Simone M. Goldinger ◽  
Kristina Buder-Bakhaya ◽  
Serigne N. Lo ◽  
Andrea Forschner ◽  
Meredith McKean ◽  
...  

Medicine ◽  
2022 ◽  
Vol 101 (2) ◽  
pp. e28428
Author(s):  
Kazuya Abe ◽  
Yuichi Ishikawa ◽  
Michio Fujiwara ◽  
Hiroko Yukawa ◽  
Takeshi Yanagihara ◽  
...  

Kidney360 ◽  
2022 ◽  
pp. 10.34067/KID.0000232022
Author(s):  
Arash Rashidi ◽  
Chintan Shah ◽  
Miroslav Sekulic

This is an Early Access article. Please select the PDF button, above, to view it.


2022 ◽  
Vol 12 ◽  
Author(s):  
Xinqing Lin ◽  
Jiaxi Deng ◽  
Haiyi Deng ◽  
Yilin Yang ◽  
Ni Sun ◽  
...  

BackgroundWhile immune checkpoint inhibitors (ICIs) are a beacon of hope for non-small cell lung cancer (NSCLC) patients, they can also cause adverse events, including checkpoint inhibitor pneumonitis (CIP). Research shows that the inflammatory immune microenvironment plays a vital role in the development of CIP. However, the role of the immune microenvironment (IME) in CIP is still unclear.MethodsWe collected a cohort of NSCLC patients treated with ICIs that included eight individuals with CIP (CIP group) and 29 individuals without CIP (Control group). CIBERSORT and the xCell algorithm were used to evaluate the proportion of immune cells. Gene set enrichment analysis (GSEA) and single-sample GSEA (ssGSEA) were used to evaluate pathway activity. The ridge regression algorithm was used to analyze drug sensitivity.ResultsCIBERSORT showed significantly upregulated memory B cells, CD8+ T cells, and M1 Macrophages in the CIP group. The number of memory resting CD4+ T cells and resting NK cells in the CIP group was also significantly lower than in the Control group. The XCell analysis showed a higher proportion of Class-switched memory B-cells and M1 Macrophages in the CIP group. Pathway analysis showed that the CIP group had high activity in their immune and inflammatory response pathways and low activity in their immune exhaustion related pathway.ConclusionsIn this study, we researched CIP patients who after ICIs treatment developed an inflammatory IME, which is characterized by significantly increased activated immune cells and expression of inflammatory molecules, as well as downregulated immunosuppressive lymphocytes and signaling pathways. The goal was to develop theoretical guidance for clinical guidelines for the treatment of CIP in the future.


2022 ◽  
Vol 12 ◽  
Author(s):  
Wenjing Zhang ◽  
Yujia Kong ◽  
Yuting Li ◽  
Fuyan Shi ◽  
Juncheng Lyu ◽  
...  

BackgroundImmune checkpoint inhibitor (ICI) therapy dramatically prolongs melanoma survival. Currently, the identified ICI markers are sometimes ineffective. The objective of this study was to identify novel determinants of ICI efficacy.MethodsWe comprehensively curated pretreatment somatic mutational profiles and clinical information from 631 melanoma patients who received blockade therapy of immune checkpoints (i.e., CTLA-4, PD-1/PD-L1, or a combination). Significantly mutated genes (SMGs), mutational signatures, and potential molecular subtypes were determined. Their association with ICI responses was assessed simultaneously.ResultsWe identified 27 SMGs, including four novel SMGs (COL3A1, NRAS, NARS2, and DCC) that are associated with ICI efficacy and well-known driver genes. COL3A1 mutations were associated with improved ICI overall survival (hazard ratio (HR): 0.64, 95% CI: 0.45–0.91, p = 0.012), whereas immune resistance was observed in patients with NRAS mutations (HR: 1.42, 95% CI: 1.10–1.82, p = 0.006). The presence of the tobacco smoking-related signature was significantly correlated with inferior prognoses (HR: 1.42, 95% CI: 1.11–1.82, p = 0.005). In addition, the signature resembling that of alkylating agents and a newly discovered signature both exhibited extended prognoses (both HR < 1, p < 0.05). Based on the activities of the extracted 6 mutational signatures, we identified one immune subtype that was significantly associated with better ICI outcomes (HR: 0.44, 95% CI: 0.23–0.87, p = 0.017).ConclusionWe uncovered several novel SMGs and re-annotated mutational signatures that are linked to immunotherapy response or resistance. In addition, an immune subtype was found to exhibit favorable prognoses. Further studies are required to validate these findings.


Sign in / Sign up

Export Citation Format

Share Document